Davion Healthcare

DAVI on Nasdaq. Surgical & medical instruments & apparatus. Market value $30m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
n/a

We could not compute this from the filings.

Price to profit
n/a

The filings do not give us enough to work this out.

Return on capital
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: not known. Our list needs 70 on quality and 60 on price.

$1.68 a share, at its 1-year low

Over the past year the price has ranged from $1.65 to $12.30.

Price from Friday’s close (30 October).

Five years of cash, in billions

Five-year fundamentals are not available yet.

Health checks

  • Free cash flow positiveNot enough data
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Not enough data
  • DebtUnknown
  • Revenue growth, five yearsUnknown

Dates

Next results (estimated)
n/a
Last annual report (10-K)
30 April 2026
Next quarterly (estimated, 10-Q)
n/a

Who owns it

We don't have fund holdings for this stock yet.

Big holders and activists

1 investor owns more than 5%.

  • JACK HARRY KAYE
    Insider or founder
    34.7%−6.4 pts
    Since 19 November 2026
    What they said

    On November 19, 2026, the Reporting Person transferred an aggregate of 1,600,000 ordinary shares of the Issuer by way of four separate bona fide gifts to four individuals. The transfers were made without consideration and were not undertaken in connection with any sale,…

    Read the filing
  • RALLINSON LTD
    Insider or founder
    Sold down below 5%
    Since 11 August 2026
    What they said

    On August 11, 2026, Rallinson Corp transferred 1,245,000 Ordinary Shares of the Issuer to Jack Harry Kaye for no consideration, and Rallinson Ltd transferred 3,860,530 Ordinary Shares of the Issuer to Mr. Kaye for no consideration. Mr. Kaye is the sole director, sole shareholder…

    Read the filing

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 2 insiders bought $36,290 of shares on the open market.

  • King Susan M
    Director
    Bought
    Date
    17 November 2026
    Shares
    10,000
    Price
    $0.98
    Value
    $9,800
  • Sluyters Julian
    Director
    Bought
    Date
    16 November 2026
    Shares
    25,000
    Price
    $1.06
    Value
    $26,490

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

Davion Healthcare doesn’t file a US annual report (10-K), so we haven’t checked it.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

A big holder just moved. The deep dive shows what the business is worth.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.